Ask most hospital leadership teams what drives readmissions, and the answer tends to circle back to the same place: discharge planning. Better patient education, clearer follow-up instructions, more phone calls after the patient goes home. Those efforts aren’t wrong — they matter. But they’re aimed at the last 48 hours of an encounter that was often already headed toward a return visit from the moment the patient was admitted.
That’s the uncomfortable reframe hospital operations leaders need to sit with: by the time a discharge-education program can intervene, a meaningful share of the risk that leads to readmission has already been set in motion — by how the case was managed, how it compared to what a similar patient’s course of care should have looked like, and whether anyone was tracking that comparison in real time.
Why Discharge-Focused Programs Plateau
Discharge-education and post-discharge outreach programs are the most common readmission-reduction interventions hospitals deploy, and they typically produce real but limited improvement — then plateau. There’s a structural reason for that ceiling:
They intervene too late to change the underlying trajectory. A patient whose care during the stay drifted from what a comparable case should have required — a delayed procedure, an atypical length of stay, inconsistent care pathways — carries elevated readmission risk regardless of how well the discharge conversation goes. This is the exact window Compass Decision Support is designed to act on — flagging cases that are drifting from their expected pathway while the patient is still admitted, not after they’ve gone home.
They treat every discharge the same way. Generic follow-up protocols don’t distinguish between a patient whose stay tracked normally for their case type and one whose course of care was already an outlier. Without a way to flag which patients are actually at elevated risk, resources get spread evenly instead of where they’re needed most.
They rely on retrospective readmission rates, not case-level benchmarks. Most hospitals measure readmissions in aggregate, after the fact — a rate reported monthly or quarterly. That tells leadership whether the problem is getting better or worse in general, but it doesn’t identify which specific cases, units, or care pathways are driving the number, or why.
They don’t connect back to case mix. A readmission rate in isolation doesn’t say much. A readmission rate for a specific DRG cohort, compared against what similar cohorts at comparable institutions experience, says a great deal — and that comparison is the piece most programs are missing.
The Alternative: Treating Readmission Risk as a Case-Mix-Standardized Signal
A different approach starts earlier and asks a different question. Instead of “how do we improve the discharge conversation,” it asks:
“Which patients, right now, are on a trajectory that deviates from what their case type would predict — and why?”
That requires standardizing cases into comparable cohorts first, using DRG methodology to group clinically similar patients, so that “deviation” means something specific rather than a vague sense that a stay felt unusually long or complicated. Once that standardized baseline exists, a few things become possible that a generic discharge program can’t offer: this is the operating model behind Hosdatia, which gives hospital and clinic teams a standardized, case-mix-based view of operational and financial performance.
Risk becomes visible during the stay, not after discharge. When a case is tracking outside the expected pattern for its DRG cohort — an atypical length of stay, an unusual complication profile — that’s a signal worth acting on while the patient is still admitted, not a data point to review next quarter.
Interventions can be targeted, not universal. Instead of applying the same follow-up protocol to every discharged patient, care teams can focus additional coordination and follow-up resources on the cases that are actually elevated-risk, based on how their course of care compared to a standardized benchmark.
Readmissions get evaluated in context. A readmission following a case that already showed multiple deviations from its expected pathway tells a very different story than a readmission following a case that tracked normally throughout. Case-mix standardization makes that distinction visible instead of collapsing every readmission into the same statistic.
Hospitals can benchmark against peers, not just their own history. Comparing a hospital’s readmission performance for a given case type against comparable institutions — rather than only against its own trend line — answers a more useful question: not “are we better than we were,” but “are we actually performing well.”
Why This Matters for Both Hospitals and Insurers
Readmissions sit at an unusual intersection: they’re a quality and cost problem for hospitals, and a cost and risk problem for insurers, often for the same underlying patient. A hospital absorbing the operational and reputational cost of a preventable readmission and an insurer absorbing the claim are looking at the same event from two different sides of the same ledger.
That shared exposure is exactly why case-mix-standardized visibility benefits both sides. A hospital that can identify elevated-risk cases early reduces avoidable readmissions before they happen. A payer that can see which DRG cohorts and which provider partners are generating excess readmissions across a network can have a fundamentally more productive conversation about performance than one relying on retrospective claims review months after the fact. On the payer side, this is exactly the kind of cross-network visibility Insuria is built to provide.
What Leadership Should Be Asking Instead
For hospital COOs, CFOs, and quality leaders evaluating their readmission strategy, the useful question isn’t “how do we improve our discharge process.” It’s: do we have a standardized way to know, while a patient is still admitted, whether their case is tracking toward a trajectory that historically correlates with readmission — and can we act on that signal before discharge, not after?
For insurers and payer organizations, the parallel question is whether readmission risk is something they can only measure in aggregate after claims are adjudicated, or something they can see emerging, cohort by cohort, in time to engage proactively with provider partners.
Discharge education will always have a role. But it’s a tool for managing risk at the very end of an encounter that, in many cases, was already shaped by decisions made days earlier — decisions that are only visible if there’s a standardized way to compare a case against what it should have looked like. That standardized comparison is what Avedian’s proprietary DRG engine makes possible across inpatient, outpatient, and population health.
